English | 简体中文 | 繁體中文 | 한국어
Share:
Orion and Propeller Health partner to bring new digital medicines to people with asthma and COPD

Orion Corporation                                  Press release  11 February 2019 at 4.00 p.m. EET

Orion and Propeller Health partner to bring new digital medicines to people with asthma and COPD

Orion Corporation and Propeller Health, a leading digital therapeutics company, today announced a partnership to connect the Easyhaler® line of inhalers for asthma and COPD to Propeller's digital medicine platform.

The partnership will expand Propeller's presence in Europe, where Orion serves patients across several countries. Propeller's platform currently covers more than 90 percent of inhaled medicines for asthma and COPD on the market.

Orion's existing line of Easyhaler® products will connect to Propeller's digital medicine platform via a small, custom-built sensor. The sensor, which is being developed collaboratively under this agreement, attaches to the inhaler and pairs with a mobile app. Propeller automatically tracks medication use and provides personal feedback and insights that help individuals and their doctors manage and reduce symptoms.

Development of the sensor will begin in 2019, with clinical trials, possible real world evidence projects and a broader commercial rollout to follow.

"By connecting Easyhaler® to Propeller's digital platform, we are giving our patients and their providers a new ability to improve the user experience of Easyhaler products and help patients better adhere to the treatments," said Satu Ahomäki, Orion's Senior Vice President, Commercial Operations. "We are thrilled to take this step to reduce the burden of asthma and COPD via a digital companion to our medicine."

"People and their physicians are eager for medicines that put digital to work to improve their treatments and quality of life," said David Van Sickle, co-founder and CEO of Propeller Health. "This partnership with Orion is another significant step toward reducing the burden of chronic respiratory disease for people around the world."

About Orion
Orion is a globally operating Finnish pharmaceutical company - a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are central nervous system (CNS) disorders, oncology and respiratory diseases for which Orion develops inhaled Easyhaler® pulmonary drugs. Orion's net sales in 2018 amounted to EUR 977 million and the company had about 3,200 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki. For more information, visit www.orion.fi.

About Propeller Health

Propeller Health is a leading digital therapeutics company dedicated to the development and commercialization of measurably better medicines. Propeller creates products to more effectively treat chronic respiratory disease and improve clinical outcomes for patients through connectivity, analytics, and companion digital experiences. The Propeller platform is used by patients, physicians and healthcare organizations in the United States, Europe and Asia. Propeller Health is a wholly owned subsidiary of ResMed (NYSE: RMD, ASX: RMD). For more information, visit www.propellerhealth.com

Further information:

Satu Ahomäki
Senior Vice President, Commercial Operations, Orion Corporation
Tel. +358 (0)50 966 7616
[email protected]

Media Contacts:

Terhi Ormio
Vice President, Communications, Orion Corporation
Tel. +358 (0)50 966 4646
[email protected]

Rachel Fields
Propeller Health
+ 001 630 901 8625
[email protected]

Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland

Orion is a globally operating Finnish pharmaceutical company - a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are central nervous system (CNS) disorders, oncology and respiratory diseases for which Orion develops inhaled Easyhaler® pulmonary drugs. Orion's net sales in 2018 amounted to EUR 977 million and the company had about 3,200 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.




This announcement is distributed by West Corporation on behalf of West Corporation clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Orion Oyj via Globenewswire

Copyright © Thomson Reuters 2019. All rights reserved.
Press Releases
Acquisition of API business completed  
Feb 15, 2019 18:39 ET
ING Group 2018 SREP process completed  
Feb 15, 2019 18:00 ET
VALMET Oyj: ACQUISITION OF OWN SHARES 15.02.2019  
Feb 15, 2019 17:28 ET
Asiakastieto Group Plc's Notice to the Annual General Meeting  
Feb 15, 2019 15:01 ET
AB Traction: Year end report 2018  
Feb 15, 2019 13:30 ET
Eastman Board Declares Dividend  
Feb 15, 2019 05:59 ET
Mark Costa to Address the Barclays Industrials Select Conference  
Feb 13, 2019 23:29 ET
CLX Communications AB (publ): CLX Communications unifies its business under a shared identity and rebrands as Sinch  
Feb 13, 2019 15:29 ET
CLX Communications AB (publ): CLX Communications appoints new CMO  
Feb 8, 2019 15:59 ET
Lubrizol Honors Lake County's Outstanding STEM Teacher Team  
Feb 7, 2019 21:29 ET
More News >>
Copyright © 2019 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 10 8405 3688 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 5791 1818

Connect With us: